Intrinsic value of Oncobiologics - ONS

Previous Close

$0.70

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$0.70

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of ONS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  6
  9
  14
  20
  29
  40
  53
  70
  90
  114
  141
  172
  208
  247
  291
  338
  390
  445
  504
  566
  633
  702
  776
  852
  932
  1,016
  1,102
  1,193
  1,287
  1,384
Variable operating expenses, $m
  111
  172
  257
  373
  526
  724
  971
  1,276
  1,641
  2,073
  2,574
  3,147
  3,794
  4,514
  5,307
  6,174
  7,112
  8,119
  9,196
  10,339
  11,547
  12,819
  14,154
  15,552
  17,012
  18,534
  20,120
  21,769
  23,484
  25,267
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  111
  172
  257
  373
  526
  724
  971
  1,276
  1,641
  2,073
  2,574
  3,147
  3,794
  4,514
  5,307
  6,174
  7,112
  8,119
  9,196
  10,339
  11,547
  12,819
  14,154
  15,552
  17,012
  18,534
  20,120
  21,769
  23,484
  25,267
Operating income, $m
  -105
  -163
  -243
  -353
  -498
  -684
  -918
  -1,206
  -1,551
  -1,960
  -2,433
  -2,975
  -3,586
  -4,266
  -5,016
  -5,835
  -6,722
  -7,674
  -8,692
  -9,772
  -10,914
  -12,117
  -13,379
  -14,700
  -16,080
  -17,519
  -19,017
  -20,576
  -22,197
  -23,882
EBITDA, $m
  -101
  -156
  -234
  -339
  -478
  -658
  -883
  -1,159
  -1,491
  -1,884
  -2,339
  -2,860
  -3,447
  -4,101
  -4,822
  -5,609
  -6,461
  -7,377
  -8,355
  -9,394
  -10,491
  -11,647
  -12,861
  -14,130
  -15,457
  -16,840
  -18,281
  -19,779
  -21,338
  -22,957
Interest expense (income), $m
  1
  9
  -8
  2
  16
  34
  59
  91
  130
  179
  238
  307
  388
  480
  583
  699
  826
  965
  1,116
  1,277
  1,450
  1,634
  1,827
  2,032
  2,246
  2,470
  2,704
  2,949
  3,203
  3,468
  3,743
Earnings before tax, $m
  -114
  -155
  -245
  -368
  -532
  -743
  -1,009
  -1,336
  -1,731
  -2,197
  -2,740
  -3,363
  -4,065
  -4,850
  -5,715
  -6,661
  -7,687
  -8,790
  -9,969
  -11,222
  -12,548
  -13,944
  -15,410
  -16,946
  -18,550
  -20,223
  -21,966
  -23,779
  -25,665
  -27,625
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -114
  -155
  -245
  -368
  -532
  -743
  -1,009
  -1,336
  -1,731
  -2,197
  -2,740
  -3,363
  -4,065
  -4,850
  -5,715
  -6,661
  -7,687
  -8,790
  -9,969
  -11,222
  -12,548
  -13,944
  -15,410
  -16,946
  -18,550
  -20,223
  -21,966
  -23,779
  -25,665
  -27,625

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  32
  49
  73
  106
  149
  205
  276
  362
  466
  589
  731
  894
  1,077
  1,281
  1,507
  1,753
  2,019
  2,305
  2,611
  2,935
  3,278
  3,639
  4,019
  4,415
  4,830
  5,262
  5,712
  6,180
  6,667
  7,173
Adjusted assets (=assets-cash), $m
  32
  49
  73
  106
  149
  205
  276
  362
  466
  589
  731
  894
  1,077
  1,281
  1,507
  1,753
  2,019
  2,305
  2,611
  2,935
  3,278
  3,639
  4,019
  4,415
  4,830
  5,262
  5,712
  6,180
  6,667
  7,173
Revenue / Adjusted assets
  0.188
  0.184
  0.192
  0.189
  0.195
  0.195
  0.192
  0.193
  0.193
  0.194
  0.193
  0.192
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
  0.193
Average production assets, $m
  26
  41
  61
  89
  125
  172
  231
  304
  391
  493
  613
  749
  903
  1,074
  1,263
  1,469
  1,692
  1,932
  2,188
  2,460
  2,748
  3,051
  3,368
  3,701
  4,048
  4,411
  4,788
  5,180
  5,589
  6,013
Working capital, $m
  -42
  -65
  -97
  -141
  -199
  -274
  -368
  -483
  -621
  -784
  -974
  -1,191
  -1,436
  -1,708
  -2,008
  -2,336
  -2,691
  -3,072
  -3,480
  -3,912
  -4,369
  -4,851
  -5,356
  -5,885
  -6,438
  -7,014
  -7,613
  -8,238
  -8,887
  -9,561
Total debt, $m
  -12
  3
  25
  55
  94
  144
  208
  285
  379
  489
  617
  764
  929
  1,113
  1,316
  1,537
  1,777
  2,034
  2,309
  2,601
  2,910
  3,235
  3,576
  3,933
  4,306
  4,695
  5,100
  5,522
  5,960
  6,416
Total liabilities, $m
  28
  44
  66
  95
  135
  185
  248
  326
  419
  530
  658
  804
  969
  1,153
  1,356
  1,577
  1,817
  2,075
  2,350
  2,642
  2,950
  3,276
  3,617
  3,974
  4,347
  4,736
  5,141
  5,562
  6,001
  6,456
Total equity, $m
  3
  5
  7
  11
  15
  21
  28
  36
  47
  59
  73
  89
  108
  128
  151
  175
  202
  231
  261
  294
  328
  364
  402
  442
  483
  526
  571
  618
  667
  717
Total liabilities and equity, $m
  31
  49
  73
  106
  150
  206
  276
  362
  466
  589
  731
  893
  1,077
  1,281
  1,507
  1,752
  2,019
  2,306
  2,611
  2,936
  3,278
  3,640
  4,019
  4,416
  4,830
  5,262
  5,712
  6,180
  6,668
  7,173
Debt-to-equity ratio
  -3.840
  0.690
  3.440
  5.170
  6.280
  7.020
  7.530
  7.880
  8.130
  8.310
  8.440
  8.550
  8.620
  8.680
  8.730
  8.770
  8.800
  8.820
  8.840
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.920
  8.930
  8.930
  8.940
  8.940
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -114
  -155
  -245
  -368
  -532
  -743
  -1,009
  -1,336
  -1,731
  -2,197
  -2,740
  -3,363
  -4,065
  -4,850
  -5,715
  -6,661
  -7,687
  -8,790
  -9,969
  -11,222
  -12,548
  -13,944
  -15,410
  -16,946
  -18,550
  -20,223
  -21,966
  -23,779
  -25,665
  -27,625
Depreciation, amort., depletion, $m
  4
  6
  9
  14
  19
  26
  36
  47
  60
  76
  94
  115
  139
  165
  194
  226
  260
  297
  337
  379
  423
  469
  518
  569
  623
  679
  737
  797
  860
  925
Funds from operations, $m
  -110
  -149
  -236
  -355
  -513
  -717
  -973
  -1,289
  -1,670
  -2,122
  -2,646
  -3,247
  -3,926
  -4,684
  -5,521
  -6,435
  -7,427
  -8,493
  -9,632
  -10,844
  -12,125
  -13,475
  -14,892
  -16,376
  -17,927
  -19,544
  -21,229
  -22,982
  -24,805
  -26,700
Change in working capital, $m
  -16
  -23
  -32
  -44
  -58
  -75
  -94
  -115
  -138
  -163
  -190
  -217
  -245
  -272
  -300
  -328
  -355
  -381
  -407
  -433
  -457
  -481
  -505
  -529
  -552
  -576
  -600
  -624
  -649
  -675
Cash from operations, $m
  -94
  -126
  -204
  -311
  -455
  -642
  -880
  -1,174
  -1,532
  -1,958
  -2,457
  -3,030
  -3,682
  -4,412
  -5,221
  -6,108
  -7,072
  -8,111
  -9,225
  -10,411
  -11,668
  -12,993
  -14,387
  -15,847
  -17,375
  -18,968
  -20,629
  -22,358
  -24,156
  -26,026
Maintenance CAPEX, $m
  -3
  -4
  -6
  -9
  -14
  -19
  -26
  -36
  -47
  -60
  -76
  -94
  -115
  -139
  -165
  -194
  -226
  -260
  -297
  -337
  -379
  -423
  -469
  -518
  -569
  -623
  -679
  -737
  -797
  -860
New CAPEX, $m
  -9
  -14
  -20
  -28
  -36
  -47
  -59
  -72
  -87
  -103
  -119
  -136
  -154
  -171
  -189
  -206
  -223
  -240
  -256
  -272
  -288
  -303
  -318
  -333
  -347
  -362
  -377
  -393
  -408
  -424
Cash from investing activities, $m
  -12
  -18
  -26
  -37
  -50
  -66
  -85
  -108
  -134
  -163
  -195
  -230
  -269
  -310
  -354
  -400
  -449
  -500
  -553
  -609
  -667
  -726
  -787
  -851
  -916
  -985
  -1,056
  -1,130
  -1,205
  -1,284
Free cash flow, $m
  -106
  -144
  -230
  -348
  -505
  -708
  -965
  -1,282
  -1,666
  -2,121
  -2,652
  -3,261
  -3,951
  -4,722
  -5,575
  -6,508
  -7,521
  -8,612
  -9,779
  -11,020
  -12,334
  -13,719
  -15,174
  -16,698
  -18,291
  -19,953
  -21,685
  -23,487
  -25,361
  -27,309
Issuance/(repayment) of debt, $m
  -26
  15
  22
  30
  39
  50
  63
  78
  93
  110
  128
  146
  165
  184
  203
  221
  240
  258
  275
  292
  309
  325
  341
  357
  373
  389
  405
  421
  438
  455
Issuance/(repurchase) of shares, $m
  151
  157
  248
  372
  536
  749
  1,016
  1,345
  1,741
  2,210
  2,755
  3,379
  4,084
  4,870
  5,738
  6,686
  7,714
  8,819
  10,000
  11,255
  12,582
  13,980
  15,448
  16,985
  18,591
  20,266
  22,011
  23,826
  25,714
  27,676
Cash from financing (excl. dividends), $m  
  125
  172
  270
  402
  575
  799
  1,079
  1,423
  1,834
  2,320
  2,883
  3,525
  4,249
  5,054
  5,941
  6,907
  7,954
  9,077
  10,275
  11,547
  12,891
  14,305
  15,789
  17,342
  18,964
  20,655
  22,416
  24,247
  26,152
  28,131
Total cash flow (excl. dividends), $m
  19
  28
  39
  53
  71
  91
  114
  140
  169
  199
  231
  264
  298
  332
  366
  399
  432
  465
  496
  527
  557
  586
  616
  644
  673
  702
  731
  760
  791
  822
Retained Cash Flow (-), $m
  -151
  -157
  -248
  -372
  -536
  -749
  -1,016
  -1,345
  -1,741
  -2,210
  -2,755
  -3,379
  -4,084
  -4,870
  -5,738
  -6,686
  -7,714
  -8,819
  -10,000
  -11,255
  -12,582
  -13,980
  -15,448
  -16,985
  -18,591
  -20,266
  -22,011
  -23,826
  -25,714
  -27,676
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -132
  -129
  -208
  -318
  -466
  -658
  -902
  -1,204
  -1,572
  -2,011
  -2,524
  -3,115
  -3,786
  -4,538
  -5,372
  -6,287
  -7,281
  -8,354
  -9,504
  -10,728
  -12,025
  -13,394
  -14,833
  -16,341
  -17,918
  -19,565
  -21,280
  -23,066
  -24,923
  -26,854
Discount rate, %
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
  -125
  -115
  -174
  -248
  -335
  -435
  -543
  -657
  -769
  -874
  -966
  -1,039
  -1,089
  -1,113
  -1,110
  -1,079
  -1,025
  -950
  -860
  -760
  -656
  -552
  -453
  -362
  -282
  -214
  -158
  -113
  -79
  -53
Current shareholders' claim on cash, %
  50.0
  1.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

FINANCIAL RATIOS  of  Oncobiologics (ONS)

Valuation Ratios
P/E Ratio -0.3
Price to Sales 5.3
Price to Book -3.2
Price to Tangible Book
Price to Cash Flow -0.4
Price to Free Cash Flow -0.3
Growth Rates
Sales Growth Rate -40%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -88.9%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity -60%
Total Debt to Equity -180%
Interest Coverage -52
Management Effectiveness
Return On Assets -176.3%
Ret/ On Assets - 3 Yr. Avg. -195.8%
Return On Total Capital 3533.3%
Ret/ On T. Cap. - 3 Yr. Avg. 1477.3%
Return On Equity 311.8%
Return On Equity - 3 Yr. Avg. 201.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -1666.7%
EBITDA Margin - 3 Yr. Avg. -903%
Operating Margin -1733.3%
Oper. Margin - 3 Yr. Avg. -935.6%
Pre-Tax Margin -1766.7%
Pre-Tax Margin - 3 Yr. Avg. -963.7%
Net Profit Margin -1766.7%
Net Profit Margin - 3 Yr. Avg. -954.1%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. -2.6%
Payout Ratio 0%

ONS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ONS stock intrinsic value calculation we used $3.811519 million for the last fiscal year's total revenue generated by Oncobiologics. The default revenue input number comes from 0001 income statement of Oncobiologics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ONS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for ONS is calculated based on our internal credit rating of Oncobiologics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Oncobiologics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ONS stock the variable cost ratio is equal to 1825%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ONS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 62.8% for Oncobiologics.

Corporate tax rate of 27% is the nominal tax rate for Oncobiologics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ONS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ONS are equal to 434.3%.

Life of production assets of 6.5 years is the average useful life of capital assets used in Oncobiologics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ONS is equal to -690.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-33.650975 million for Oncobiologics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 72.184 million for Oncobiologics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Oncobiologics at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
MNTA Momenta Pharma 13.27 1.19  str.sell
AMGN Amgen 192.45 130.16  sell
PDLI PDL BioPharma 2.91 16.84  str.buy
CLDX Celldex Therap 0.340 0.12  str.sell
MRK Merck&Co 74.84 33.05  str.sell
AST Asterias Bioth 1.30 0.08  str.sell
BTX BioTime 1.82 0.31  str.sell
LLY Eli Lilly 112.20 67.15  sell
CYTR CytRx 0.670 0.13  str.sell

COMPANY NEWS

▶ Oncobiologics Advances ONS-5010 into wet AMD Clinical Trial   [Nov-06-18 09:00AM  GlobeNewswire]
▶ Oncobiologics Enters into First CDMO Contract   [Jun-13-18 03:04PM  GlobeNewswire]
▶ Oncobiologics Appoints Randy Thurman to Board of Directors   [Apr-17-18 09:00AM  GlobeNewswire]
▶ Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?   [Mar-22-18 01:48PM  Simply Wall St.]
▶ Oncobiologics Announces Term Extension of Series A Warrants   [Feb-09-18 09:00AM  GlobeNewswire]
▶ Does Oncobiologics Incs (ONS) Recent Track Record Look Strong?   [Dec-04-17 07:00PM  Simply Wall St.]
▶ Breaking Down Oncobiologics Incs (ONS) Ownership Structure   [Oct-20-17 04:56PM  Simply Wall St.]
▶ ETFs with exposure to Oncobiologics, Inc. : July 4, 2017   [Jul-04-17 03:17PM  Capital Cube]
▶ ETFs with exposure to Oncobiologics, Inc. : June 5, 2017   [Jun-05-17 02:37PM  Capital Cube]
▶ Oncobiologics Secures Additional Funding   [Apr-17-17 09:00AM  GlobeNewswire]
▶ ETFs with exposure to Oncobiologics, Inc. : April 7, 2017   [Apr-07-17 05:14PM  Capital Cube]
▶ Worst Performing Biotech IPOs of 2016   [Oct-10-16 10:11AM  Investopedia]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.